SCHEMBL5776502

SCHEMBL5776502

CN=Cc1ccc(NC(C)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 1/20 0.61
SMN1; SMN2 Q16637 7/20 0.58
RAB9A P51151 7/20 0.58
NPC1 O15118 5/20 0.58
LMNA P02545 2/20 0.58
HTT P42858 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 3/20 0.54
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 4/20 0.53
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 1/20 0.53
BRD4 O60885 1/20 0.53
NR1I2 O75469 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MB P02144 1/20 0.53
CYP1A1 P04798 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776498 1.00 NOX1 (0.61) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL11746811 0.86 NOX1 (0.63) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL7996474 0.83 NOX1 (0.59) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL203520 0.81 NOX1 (0.67) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL203519 0.81 NOX1 (0.67) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL6076757 0.80 RAB9A (0.59) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL6076761 0.80 RAB9A (0.59) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL20878229 0.80 SMN1; SMN2 (0.59) NOX1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL7941711 0.79 SMN1; SMN2 (0.64) NOX1SMN1; SMN2RAB9ANPC1HTT
SCHEMBL7941715 0.79 SMN1; SMN2 (0.64) NOX1SMN1; SMN2RAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT NOX1 1745/4885SMN1; SMN2 2146/4885RAB9A 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.